- Home
- ELVN vs BBNX Comparison
ELVN vs BBNX Comparison
Compare ELVN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- BBNX
- Stock Information
- Founded
- ELVN 2016
- BBNX 2015
- Country
- ELVN United States
- BBNX United States
- Employees
- ELVN N/A
- BBNX N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- ELVN Health Care
- BBNX Health Care
- Exchange
- ELVN Nasdaq
- BBNX Nasdaq
- Market Cap
- ELVN 927.8M
- BBNX 841.5M
- IPO Year
- ELVN 2020
- BBNX 2025
- Fundamental
- Price
- ELVN $21.30
- BBNX $17.89
- Analyst Decision
- ELVN Strong Buy
- BBNX Strong Buy
- Analyst Count
- ELVN 5
- BBNX 10
- Target Price
- ELVN $39.60
- BBNX $25.20
- AVG Volume (30 Days)
- ELVN 594.3K
- BBNX 504.1K
- Earning Date
- ELVN 08-12-2025
- BBNX 08-06-2025
- Dividend Yield
- ELVN N/A
- BBNX N/A
- EPS Growth
- ELVN N/A
- BBNX N/A
- EPS
- ELVN N/A
- BBNX N/A
- Revenue
- ELVN N/A
- BBNX $69,830,000.00
- Revenue This Year
- ELVN N/A
- BBNX $32.79
- Revenue Next Year
- ELVN N/A
- BBNX $36.59
- P/E Ratio
- ELVN N/A
- BBNX N/A
- Revenue Growth
- ELVN N/A
- BBNX 38911.17
- 52 Week Low
- ELVN $13.30
- BBNX $8.89
- 52 Week High
- ELVN $30.03
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- ELVN 55.53
- BBNX N/A
- Support Level
- ELVN $18.53
- BBNX N/A
- Resistance Level
- ELVN $24.11
- BBNX N/A
- Average True Range (ATR)
- ELVN 1.96
- BBNX 0.00
- MACD
- ELVN 0.15
- BBNX 0.00
- Stochastic Oscillator
- ELVN 55.68
- BBNX 0.00
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.